|
 |
MegaceThis page contains recent news articles, when available, and an overview of Megace but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Megace is a progesterone-based prescription medication, but only for short-term use. Gabapentin and Clonidine are other drugs used for menopausal hot ... Herald.ie Par Pharmaceutical Net Surges Above Estimates; Revenue Doubles - Nov 6, 2009 Sales of Megace ES, its first marketed brand-name drug, for AIDS-related weight loss, rose 12% to $19.1 million from the prior quarter. Wall Street Journal FDA Approves Megace ES for Anorexia, Cachexia, or Unexplained, … - Jul 6, 2005 WOODCLIFF LAKE, NJ -- July 6, 2005 -- Par Pharmaceutical Companies, Inc. today announced that the US Food and Drug Administration (FDA) has approved Megace® ... DG News Par Pharmaceutical Announces FDA Approval of Megace(R) ES for … - Jun 7, 2005 WOODCLIFF LAKE, NJ, July 6 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that the US Food and Drug Administration (FDA) has ... Euro am Sonntag Par Pharmaceuticals swings to 2Q loss - Aug 8, 2008 The company cited a mix of increased competition on generic products, lower sales of the anorexia and malnutrition treatment Megace ES, and lower royalties ... Boston Globe Article: Par loses ground in 2nd quarter - The Record (Bergen County,... - Jul 29, 2005 Pharmacology: Megace ES is a concentrated oral suspension formulation of ... The approval of Megace ES represents the first ... product developed by Par to ... Pay-Per-View - The Record - HighBeam Research Event Brief of Q4 2005 Par Pharmaceutical Companies, Inc. Earnings … - Feb 28, 2006 The EPS forecast for 2006 is based on Megace ES sales reaching $70m. ... Megace ES was lower than anticipated due to inventory. 1. Not all of the Megace ES ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Par Pharmaceutical Reports Sales and Earnings for 2005. - Feb 28, 2006 In its first year of marketing, the appetite stimulant Megace ES (megestrol ... Introduced in the third quarter, Megace ES represents Par's first branded ... Free with registration - PR Newswire - AccessMyLibrary.com … Megace(R) ES to July 29, 2005; Summer Launch of Megace(R) ES Still... - Apr 18, 2005 FDA Extends PDUFA Date For Megace(R) ES to July 29, 2005; Summer Launch of Megace(R) ES Still Anticipated. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … Pharmaceutical (PRX) Receives Patent Relating to Megace ES 625... - Sep 5, 2006 Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced that a new patent has been issued by the US Patent and Trademark Office (PTO) relating to Megace ES ... StreetInsider.com - StreetInsider.com (subscription) … : Par Pharmaceutical Announces FDA Approval of Megace(R) ES for … - Jul 6, 2005 Par Pharmaceutical Announces FDA Approval of Megace(R) ES for Anorexia, Cachexia, or an Unexplained, Significant Weight Loss in Patients With a Diagnosis of ... Pay-Per-View - PR Newswire - HighBeam Research Megace - Megestrol acetate - Medical Drug - Aug 2, 2007 Megestrol acetate is a man-made substance called progestin which is similar to the female hormone progesterone. Many breast cancers are affected by hormones ... Virtual Medical Centre - The Virtual Medical Centre … (R) Technology Patent Issued Covering Par's Megace(R) ES. - PR … - Sep 5, 2006 Patent Recognizes Minimal Food Effect Associated with Megace ES ... In 2005, the U.S. Food and Drug Administration (FDA) approved Megace ES for the ... Pay-Per-View - PR Newswire - HighBeam Research Q1 and Q2 2007 Par Pharmaceutical Companies, Inc. Earnings … - Nov 21, 2007 We continue to grow Megace ES, now annualizing at over $80 million. And we terminated noncore assets such as Par 101. Looking ahead at some key milestones ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Event Brief of Q2 2005 Par Pharmaceutical Companies, Inc. Earnings … - Jul 28, 2005 Co. anticipates that Megace ES is going to contribute quite a bit to future quarters ... quarter, which is largely Megace ES and the branded infrastructure, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com MyFox Wausau | Megace - Uses, Side Effects, Interactions, Warnings, … - Mar 9, 2007 By Bristol-Myers Squibb. Megestrol belongs to a group of medicines known as progestagens. It prevents the release of a hormone required for production of ... MyFox Wausau FDA OK's Par's generic Pfizer Dostinex - Dec 29, 2005 Par noted that it received approval this year for Megace ES, its first branded pharmaceutical product, and the firm said it expects to launch its second ... United Press International cancerfacts.com - About Breast Cancer - Jun 6, 2007 Progestins (progesterone-like drugs such as megestrol acetate, Megace®) reduce the effect of estrogen on breast cancer cells. They are traditionally used in ... Cancerfacts.com FDA Approvals: BiDil, Megace ES, Aczone - Jul 14, 2005 July 14, 2005 -- The US Food and Drug Administration (FDA) has approved isosorbide dinitrate/hydralazine HCl tablets for use in self-identified black ... Medscape Patrick G. LePore Elected to Board of Directors of Par Pharmaceutical... - May 22, 2006 In 2005, Par received approval for and introduced Megace(R) ES, its first branded pharmaceutical product, and will launch Cesamet(TM), its second branded ... RedOrbit Event Brief of Q4 2004 Par Pharmaceutical Companies, Inc. Earnings … - Feb 24, 2005 During 4Q04, PRX had share and price pressure with Megace and also price pressure on Paxil. ... Megace declined from $88m to $68m. 2. 4Q04 sales of $13m, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com FDA approval of branded drug is a first for Par | Article from The... - Jul 7, 2005 With Megace ES, the Woodcliff Lake company will expand from its traditional ... Par touted two key improvements for Megace ES, a liquid, over the original. ... Pay-Per-View - The Record - HighBeam Research … Megace(R) ES to July 29, 2005; Summer Launch of Megace(R) ES Still... - Apr 18, 2005 SPRING VALLEY, NY, April 18 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that it was notified by the US Food and Drug ... $4.95 - PR Newswire - ECNext Par diversifying into brand-new turf. - Apr 28, 2005 And then there is Megace ES, as the new branded version will be known. AIDS and cancer patients take Megace, known as a wasting treatment, either in pill or ... Free with registration - The Record - AccessMyLibrary.com [U] Pharmaceutical Resources, Inc. v. Roxane Laboratories, Inc., No.... - Nov 8, 2006 Bristol-Myers Squibb ("BMS") first developed such a product and began marketing it in the United States, upon approval in 1993, under the name Megace. ... $2.95 - U.S. District Court, District of New... - VersusLaw Par Pharmaceutical Reports First-Quarter Sales and Earnings. - May 1, 2006 However, as sales of Megace ES grow and we add additional products, ... In the first quarter, the appetite stimulant Megace ES (megestrol acetate) 625 mg/5 ... Free with registration - PR Newswire - AccessMyLibrary.com Par diversifying into brand-new turf | Article from The Record... - Apr 28, 2005 And then there is Megace ES, as the new branded version will be known. AIDS and cancer patients take Megace, known as a wasting treatment, either in pill or ... Pay-Per-View - The Record - HighBeam Research PAR RECEIVES FDA APPROVAL OF MEGACE ES FOR ANOREXIA - Jul 12, 2005 Par has received FDA approval for Megace ES, a concentrated oral suspension for the treatment of anorexia, cachexia or an unexplained, significant weight ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Par Pharmaceutical Reports First-Quarter Sales and Earnings - Aug 5, 2008 Sales of megestrol acetate oral suspension, the generic form of Megace(R), were $8.6 million and sales of fluoxetine, the generic version of Prozac(R), ... Euro am Sonntag Par Pharmaceutical Reports Third-Quarter Sales and Earnings. - Oct 27, 2005 ..."The third quarter benefited from the introduction of Megace ES and an improving gross ... However, with the successful launch of Megace ES now underway, ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Par Pharmaceutical Reports Third-Quarter Sales and … - Oct 27, 2005 Quarter Marks the Introduction of Megace(R) ES, the First Branded Pharmaceutical ... "The third quarter benefited from the introduction of Megace ES and an ... Pay-Per-View - PR Newswire - HighBeam Research Event Brief of Q3 2005 Par Pharmaceutical Companies, Inc. Earnings … - Oct 2, 2005 Qtr. was bolstered by new product introductions: Ultracet and Megace ES. 1. ... Co. deferred a significant amount of Megace ES to 4Q05. 1. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Par loses ground in 2nd quarter; drug maker posts disappointing... - Jul 29, 2005 Meanwhile, the company launched Megace ES, its first branded drug, just this month, ... Several analysts cited high spending on Megace ES as reason for the ... Free with registration - The Record - AccessMyLibrary.com Par to Distribute Generic Versions of Augmentin(R) and Amoxil(R). - Dec 16, 2005 Inc. The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace(R) ES, for specialty markets. ... Free with registration - PR Newswire - AccessMyLibrary.com Par to Acquire Eight Generic Products. - Dec 22, 2005 In 2005, Par received approval for and introduced Megace(R) ES, its first branded pharmaceutical product, and expects to launch its second in early 2006. ... Free with registration - PR Newswire - AccessMyLibrary.com Par Pharmaceutical's Partner Receives Final Approval to Market... - Dec 5, 2005 Inc. The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace(R) ES, for specialty markets. ... Free with registration - PR Newswire - AccessMyLibrary.com Par Pharmaceutical to Present at First Albany Capital Annual Growth … - Nov 29, 2005 Inc. The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace(R) ES, for specialty markets. ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Par Pharmaceutical Launches www.MegaceES.com. - PR … - Nov 10, 2005 Megace ES and megestrol acetate oral suspension are indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in ... Pay-Per-View - PR Newswire - HighBeam Research Q3 2007 Par Pharmaceutical Companies, Inc. Earnings Conference Call -... - Dec 20, 2007 Higher royalties driven by the 2006 fourth quarter launch of ondansetron tablets of $8.4 million, increased sales of Megace ES with net sales of $58.2 ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com [U] Pharmaceutical Resources, Inc. v. Roxane Laboratories, Inc., No.... - Apr 9, 2008 In about 1996, when Par first decided to develop a generic version of BMS's Megace(r) product, Par set out to copy BMS's exact formulation. ... $2.95 - U.S. District Court, District of New... - VersusLaw Press Release: Allegra(R) (fexofenadine hydrochloride) Oral Suspension... - Mar 13, 2007 MEGACE(R) (megestrol acetate) Oral Suspension. The drug is indicated for the treatment ... MEGACE Oral Suspension is a synthetic derivative of the naturally ... Pay-Per-View - PR Newswire - HighBeam Research Finance; Par Pharmaceutical reports first-quarter revenues of 78% to ... - May 31, 2006 In the first quarter, the appetite stimulant Megace ES (megestrol acetate) 625 ... Megace ES holds a 15.6% share of new prescriptions in the US market for ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: Wyeth Receives FDA Approval of Protonix for Delayed- … - Nov 15, 2007 MEGACE(R) (megestrol acetate) Oral Suspension. The drug is indicated for the treatment ... MEGACE Oral Suspension is a synthetic derivative of the naturally ... Pay-Per-View - PR Newswire - HighBeam Research GETTING AHEAD | Article from The Record (Bergen County, NJ) | … - Mar 4, 2008 Megace ES, an appetite builder used by patients with AIDS, is Par's first non-generic product. Par rose $1.54, or 8.7 percent, to $19.23 Monday. ... Pay-Per-View - The Record - HighBeam Research Is There Any Role For Thalidomide As A Monotherapy In The … - Mar 9, 2006 In this report by Lee and colleagues, thalidomide as a monotherapy is compared to medroxyprogesterone acetate (Megace). Of note, Megace was the first ... Medical News Today - Medical News Today (press release) Par Pharmaceutical Launches www.MegaceES.com. - Nov 10, 2005 Megace ES and megestrol acetate oral suspension are indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in ... $4.95 - PR Newswire - ECNext Press Release: FDA Approves New Formulation for NEXIUM. - PR … - Oct 24, 2006 MEGACE(R) (megestrol acetate) Oral Suspension. The drug is indicated for the treatment ... MEGACE Oral Suspension is a synthetic derivative of the naturally ... Pay-Per-View - PR Newswire - HighBeam Research Patients With HIV-Associated Wasting Gain More Weight With … - Dec 19, 2005 Megace ES, a concentrated megestrol acetate oral suspension formulated using the ... In unfed conditions, the absorption of Megace ES is substantially less ... RedOrbit Par Pharmaceutical Reports Second-Quarter Sales and Earnings - Jul 28, 2005 Following this month's approval and introduction of Megace(R) ES, ... Sales of megestrol acetate oral suspension, the generic form of Megace, ... RedOrbit Par Pharmaceutical Announces Results of Phase II Proof-of-Concept … - Jul 26, 2005 Par's recently approved Megace ES (megestrol acetate) 625 mg/ 5 mL concentrated ... Megace ES and megestrol acetate oral suspension are indicated for the ... $4.95 - PR Newswire - ECNext Finance; Par Pharmaceutical reports total revenues of $433.2 million... - Mar 28, 2006 In its first year of marketing, the appetite stimulant Megace ES (megestrol ... Introduced in the third quarter, Megace ES represents Par's first branded ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Article: Strativa Pharmaceuticals to focus on supportive care. - Oct 1, 2007 Megace ES generated more than $19 million in net sales in the second quarter of 2007. Megace ES sales are currently annualizing at over $75 million ... Pay-Per-View - BIOTECH Patent News - HighBeam Research Tilgjengelighet av megestrol tabletter på norske apotek - Apr 23, 2008 Bakgrunnen for dette er mangel på Megace 160 mg (megestrolacetat) tabletter i Norge ... Pasienter som bruker Megace bør få informasjon om at de kan få ... Statens legemiddelverk Press Release: Patients With HIV-Associated Wasting Gain More Weight ... - Dec 19, 2005 Megace ES, a concentrated megestrol acetate oral suspension formulated using the ... In unfed conditions, the absorption of Megace ES is substantially less ... Pay-Per-View - PR Newswire - HighBeam Research Involuntary weight loss: interview with Lisa Capaldini, MD(Interview) - Mar 25, 2005 We noted a recent report on a new formulation of Megace (megestrol acetate), ... Instead, these patients need an appetite stimulant, such as Megace, ... Pay-Per-View - AIDS Treatment News - Factiva, from Dow Jones Par Pharmaceutical Reports Sales and Earnings for 2004. - Feb 24, 2005 We look forward to introducing the advanced formulation of Megace(R), ... Par licensed the Megace(R) name from Bristol-Myers Squibb Company. ... $4.95 - PR Newswire - ECNext Par Pharmaceutical Reports First-Quarter Sales and Earnings; Company ... - Apr 28, 2005 Sales of megestrol acetate oral suspension, the generic form of Megace(R), were $8.6 million and sales of fluoxetine, the generic version of Prozac(R), ... $4.95 - PR Newswire - ECNext PRX - Par Pharmaceutical Cos Inc Company Profile - CNNMoney.com - Dec 12, 2008 Megace(r) ES, its first brand product, is indicated for the treatment of anorexia, cachexia or any unexplained weight loss in patients with a diagnosis of ... CNNMoney.com Press Release: Actavis Launches Griseofulvin Oral Suspension in the... - Jul 31, 2007 MEGACE(R) (megestrol acetate) Oral Suspension. The drug is indicated for the treatment ... MEGACE Oral Suspension is a synthetic derivative of the naturally ... Pay-Per-View - PR Newswire - HighBeam Research Re-induction of hormone sensitivity to diethylstilboestrol in... - Jan 8, 2008 Megace was unsuccessfully trialled in December 2006, following further relapse. In February 2007, the patient was rechallenged with DES leading to a marked ... Nature.com Loislaw Federal District Court Opinions - PHARMACEUTICAL … - Nov 8, 2006 Bristol-Myers Squibb ("BMS") first developed such a product and began marketing it in the United States, upon approval in 1993, under the name Megace. ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Press Release: Media Advisory: Voluntary Drug Recall - Ortho-McNeil … - Apr 10, 2007 MEGACE(R) (megestrol acetate) Oral Suspension. The drug is indicated for the treatment ... MEGACE Oral Suspension is a synthetic derivative of the naturally ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Lupin Receives US FDA Approval for Novel Formulation … - Apr 12, 2007 MEGACE(R) (megestrol acetate) Oral Suspension. The drug is indicated for the treatment ... MEGACE Oral Suspension is a synthetic derivative of the naturally ... Pay-Per-View - PR Newswire - HighBeam Research New formulations.(MetroGel 1% Topical Gel introduced)(Clarinex … - Aug 8, 2005 Megace ES, Par's first approval for a specialty market, is indicated for the treatment of ... The trade name Megace was licensed from Bristol-Myers Squibb. ... Free with registration - Drug Topics - AccessMyLibrary.com Should we use appetite stimulants for malnourished elderly patients?(... - Sep 1, 2007 The Megace ES package insert notes the following potential adverse effects: ... Only 1 appetite stimulate, megestrol acetate oral suspension (Megace) at 400 ... Free with registration - Journal of Family Practice - AccessMyLibrary.com Press Release: Par Pharmaceutical Reports Sales and Earnings for... - Feb 28, 2006 Par Looks Forward to Megace(R) ES Sales of Approximately $70 Million in 2006 ... Pharmacology: Megace ES is a concentrated oral suspension formulation of ... Pay-Per-View - PR Newswire - HighBeam Research Finance; Pharma company announces record financial results - Mar 21, 2005 If approved, Par expects to market megestrol acetate NCD under the Megace brand name. Par licensed the Megace name from Bristol-Myers Squibb company. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Finance; Pharma company announces record financial results - Mar 25, 2005 If approved, Par expects to market megestrol acetate NCD under the Megace brand name. Par licensed the Megace name from Bristol-Myers Squibb company. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones PROGESTIN (Oral route, Parenteral route, Vaginal route).(Drug... - May 1, 2007 Megace ES * Mirena * Ovrette * Plan B * Prochieve * Prodrox ... Megace Os Dosage forms -- * Tablet * Gel/Jelly * Kit * Suspension * Capsule, Liquid Filled ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Press Release: European Union's CHMP Adopts Positive Opinion for … - Sep 22, 2006 MEGACE(R) (megestrol acetate) Oral Suspension. The drug is indicated for the treatment ... MEGACE Oral Suspension is a synthetic derivative of the naturally ... Pay-Per-View - PR Newswire - HighBeam Research Article: Cephalexin for oral suspension.(Products) - Skin & Allergy... - Nov 1, 2005 MEGACE(R) (megestrol acetate) Oral Suspension. The drug is indicated for the treatment ... MEGACE Oral Suspension is a synthetic derivative of the naturally ... Pay-Per-View - Skin & Allergy News - HighBeam Research Q1 2006 Par Pharmaceutical Companies, Inc. Earnings Conference Call -... - May 1, 2006 Why don't we go now on to the Megace ES topic? And yes, I know before you ask, we still are forecasting $70 million of Megace ES sales this year. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Progestins --For Noncontraceptive Use (Systemic). - Oct 27, 2005 Hylutin(1) Megace(4) Prochieve(6) Prodrox(1) Prometrium(6) Pro-Span(1) Provera(3) ... Depo-Provera(3) Gen-Medroxy(3) Megace(4) Megace OS(4) Norlutate(5) ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Press Release: Introducing Strativa Pharmaceuticals. - PR Newswire | ... - Sep 28, 2007 ..."Our proprietary ... first product, Megace ES, in July 2005 ... while taking ... Reports on ... while taking Megace ES. Strativa ... resources, Strativa ... Pay-Per-View - PR Newswire - HighBeam Research USA biotech: GTx drug shows promise against cachexia - Oct 14, 2008 However, Dobs noted that patients can be treated with products like Megace to help maintain nutritional intake. Megace (Par Pharmaceuticals Inc.) currently ... $34.00 - EIU Country Analysis - Alacra Store Press Release: FDA Approves Allegra(R) (fexofenadine hydrochloride) … - Oct 18, 2006 Megace(R) Oral Suspension received orphan drug ... for Megace(R) Oral Suspension ... Megace(R) brand oral suspension is currently prescribed ... constitute ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Par Pharmaceutical Reports First-Quarter Sales and … - Apr 28, 2005 Sales of megestrol acetate oral suspension, the generic form of Megace(R), were $8.6 million and sales of fluoxetine, the generic version of Prozac(R), ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Par Pharmaceutical Reports Sales and Earnings for... - Feb 24, 2005 We look forward to introducing the advanced formulation of Megace(R), ... Par licensed the Megace(R) name from Bristol-Myers Squibb Company. ... Pay-Per-View - PR Newswire - HighBeam Research Immtech and Par Enter Licensing Agreement on Pafuramidine for … - Jun 12, 2007 ..."Par's recent success with commercializing Megace ES(R) for AIDS wasting disease demonstrates their clear understanding of the needs of both patients and ... Free with registration - PR Newswire - AccessMyLibrary.com Par Pharmaceutical Files Form 10-Q/A for Third Quarter of 2006. - Jul 30, 2007 Sales of Megace(R) ES (megestrol acetate) oral suspension, the company's first branded product, increased 46 percent to $12.7 million in the third quarter. ... $4.95 - PR Newswire - ECNext Elan Announces the Johnson & Johnson Pharmaceutical Research … - Oct 29, 2007 Megace[R] is a registered trademark owned by Bristol-Myers Squibb Company licensed to Par Pharmaceutical, Inc. Rapamune[R] is a registered trademark owned ... Free with registration - Business Wire - AccessMyLibrary.com Par Announces Agreement with Valeant to Promote Cesamet. - Nov 3, 2005 The product also represents an ideal complement to Par's Megace(R) ES and will permit us to utilize our sales force more efficiently." ... Free with registration - PR Newswire - AccessMyLibrary.com Analysis of: GTx Initiates Phase IIb Ostarine Clinical Trial For... - Jul 6, 2007 At this time we use Megace "like water" so I expect it will be used early and often as long as the price and the insurers cooperate. Gerson Lehrman Group Q4 2004 Par Pharmaceutical Companies, Inc. Earnings Conference Call -... - Feb 24, 2005 During 4Q04, PRX had share and price pressure with Megace and also price pressure on Paxil. PRX expects 2005 margins in the low to mid 40s, s significant ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Deckers Outdoor, EnerNoc, Par, World Fuel: US Equity Preview - Aug 7, 2008 The maker of the anorexia drug Megace ES reported a second- quarter loss from continuing operations of 59 cents a share. Analysts had expected profit of 13 ... Bloomberg Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First ... - Sep 6, 2007 Sales of Megace(R) ES (megestrol acetate) oral suspension, the company's first branded product, increased 174 percent to $14.4 million in the fourth quarter ... $4.95 - PR Newswire - ECNext Generic Drugs; Pharma company cleared to market Megestrol Acetate … - Mar 7, 2005 The FDA deemed MGP's drug product to be bioequivalent and, therefore, therapeutically equivalent to the listed drug MEGACE oral suspension 40 mg/mL of ... Pay-Per-View - AIDS Vaccine Week - Factiva, from Dow Jones Par Pharmaceutical Reports Third-Quarter 2007 Results. - Dec 20, 2007 This impact was offset by increased sales of higher margin products such as propranolol ER and Megace ES, lower inventory write-offs and reduced sales on ... $4.95 - PR Newswire - ECNext Press Release: Par Pharmaceutical Announces Promotions and … - Sep 20, 2005 Mr. MacPhee has been instrumental in building a marketing and sales organization, and planning and executing the launch of Megace(R) ES, Par's first branded ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Par Pharmaceutical Reports Second-Quarter Sales and … - Jul 28, 2005 Following this month's approval and introduction of Megace(R) ES, ... Sales of megestrol acetate oral suspension, the generic form of Megace, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Par Pharmaceutical Receives Final Approval to Market … - Aug 29, 2005 The Court ... FDA") for megestrol oral suspension, and therefore expects ... formulation of megestrol oral suspension. Bristol-Myers Megace ... ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Morton Grove Pharmaceuticals Cleared to Market … - Feb 10, 2005 R) The FDA deemed MGP's drug product to be bioequivalent and, therefore, therapeutically equivalent to the listed drug MEGACE(R) oral suspension 40 mg/mL of ... Pay-Per-View - PR Newswire - HighBeam Research Par Pharmaceutical Announces Promotions and Executive Staff … - Sep 20, 2005 Mr. MacPhee has been instrumental in building a marketing and sales organization, and planning and executing the launch of Megace(R) ES, Par's first branded ... $4.95 - PR Newswire - ECNext Par Pharmaceutical Cos.(RX/GENERIC DRUGS--Profiles) | Article from … - Sep 25, 2006 In 2005 Par received approval for and introduced the appetite stimulant Megace ES (megestrol acetate) 625-mg/5-mL oral suspension, its first branded ... Pay-Per-View - Chain Drug Review - HighBeam Research Par Pharmaceutical Names John A. MacPhee Senior Vice President, … - Jan 11, 2005 Megace(R) is a registered trademark of the Bristol-Myers Squibb Company. Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic ... $4.95 - PR Newswire - ECNext Morton Grove Pharmaceuticals Cleared to Market Megestrol Acetate Oral... - Feb 10, 2005 R) The FDA deemed MGP's drug product to be bioequivalent and, therefore, therapeutically equivalent to the listed drug MEGACE(R) oral suspension 40 mg/mL of ... $4.95 - PR Newswire - ECNext Par Pharmaceutical Files Form 10-Q/As for First and Second Quarters... - Jul 10, 2007 ...fluticasone nasal spray achieved sales of $77.2 million; cabergoline contributed sales of $11.9 million; sales of Megace(R) ES reached $8.5 million; ... $4.95 - PR Newswire - ECNext Generic Drugs; Pharma company cleared to market Megestrol Acetate … - Mar 8, 2005 The FDA deemed MGP's drug product to be bioequivalent and, therefore, therapeutically equivalent to the listed drug MEGACE oral suspension 40 mg/mL of ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Press Release: Par Pharmaceutical Licenses Commercialization Rights … - Jun 12, 2007 With Megace(R) ES and pafuramidine, Par's sales force would be helping to address ... Par's recent success in commercializing Megace(R) ES for AIDS wasting ... Pay-Per-View - PR Newswire - HighBeam Research Article: Par Pharmaceutical.(Pipeline) - Medical Marketing & Media | ... - Aug 1, 2005 ...find Medical Marketing & Media articles. Par Pharmaceutical announced FDA approval of Megace ES (megestrol acetate), a concentrated oral suspension fo... Pay-Per-View - Medical Marketing & Media - HighBeam Research Generic Drugs; Pharma company cleared to market Megestrol Acetate … - Mar 11, 2005 The FDA deemed MGP's drug product to be bioequivalent and, therefore, therapeutically equivalent to the listed drug MEGACE oral suspension 40 mg/mL of ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Press Release: Par Pharmaceutical Reports First-Quarter Sales and … - May 1, 2006 However, as sales of Megace ES grow and we add additional products, the dilution will diminish and the investment will be rewarded." First-Quarter Review ... Pay-Per-View - PR Newswire - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |